A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.

Titre officiel

A Phase IB/II, 2-stage, Open-label, Multicentre Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer.

Sommaire:

This study is designed to determine the efficacy and safety of durvalumab in combination with paclitaxel and multiple novel oncology therapies and durvalumab with paclitaxel alone for the treatment of first-line metastatic triple negative breast cancer.

Description de l'essai

Primary Outcome:

  • Incidence of adverse events
  • Laboratory findings
Secondary Outcome:
  • Objective response rate (ORR)
  • Progression-free survival (PFS).
  • Duration of response (DoR)
  • Overall survival (OS)
  • Blood concentration of durvalumab and novel oncology therapies
  • Presence of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies
This is a Phase IB/II, 2-stage, open-label, multicentre study to determine the efficacy and safety of durvalumab + paclitaxel + novel oncology therapies (i.e. therapies designed for immune modulation) and durvalumab + paclitaxel alone as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel triplet combinations with clinical promise using a 2-stage approach. Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 is a Phase II study. The triplet treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer